全文获取类型
收费全文 | 141篇 |
免费 | 14篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 5篇 |
基础医学 | 27篇 |
口腔科学 | 2篇 |
临床医学 | 6篇 |
内科学 | 58篇 |
皮肤病学 | 4篇 |
神经病学 | 13篇 |
特种医学 | 2篇 |
外科学 | 9篇 |
预防医学 | 7篇 |
眼科学 | 7篇 |
药学 | 4篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 11篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 4篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 9篇 |
2011年 | 8篇 |
2010年 | 3篇 |
2009年 | 2篇 |
2008年 | 4篇 |
2007年 | 5篇 |
2006年 | 2篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2002年 | 7篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1987年 | 4篇 |
1985年 | 1篇 |
1979年 | 1篇 |
1972年 | 1篇 |
1968年 | 1篇 |
1955年 | 1篇 |
1924年 | 1篇 |
排序方式: 共有155条查询结果,搜索用时 0 毫秒
81.
Tukiainen T Kettunen J Kangas AJ Lyytikäinen LP Soininen P Sarin AP Tikkanen E O'Reilly PF Savolainen MJ Kaski K Pouta A Jula A Lehtimäki T Kähönen M Viikari J Taskinen MR Jauhiainen M Eriksson JG Raitakari O Salomaa V Järvelin MR Perola M Palotie A Ala-Korpela M Ripatti S 《Human molecular genetics》2012,21(6):1444-1455
Almost 100 genetic loci are known to affect serum cholesterol and triglyceride levels. For many of these loci, the biological function and causal variants remain unknown. We performed an association analysis of the reported 95 lipid loci against 216 metabolite measures, including 95 measurements on lipids and lipoprotein subclasses, obtained via serum nuclear magnetic resonance metabolomics and four enzymatic lipid traits in 8330 individuals from Finland. The genetic variation in the loci was investigated using a dense set of 440 807 directly genotyped and imputed variants around the previously identified lead single nucleotide polymorphisms (SNPs). For 30 of the 95 loci, we identified new metabolic or genetic associations (P < 5 × 10(-8)). In the majority of the loci, the strongest association was to a more specific metabolite measure than the enzymatic lipids. In four loci, the smallest high-density lipoprotein measures showed effects opposite to the larger ones, and 14 loci had associations beyond the individual lipoprotein measures. In 27 loci, we identified SNPs with a stronger association than the previously reported markers and 12 loci harboured multiple, statistically independent variants. Our data show considerable diversity in association patterns between the loci originally identified through associations with enzymatic lipid measures and reveal association profiles of far greater detail than from routine clinical lipid measures. Additionally, a dense marker set and a homogeneous population allow for detailed characterization of the genetic association signals to a resolution exceeding that achieved so far. Further understanding of the rich variability in genetic effects on metabolites provides insights into the biological processes modifying lipid levels. 相似文献
82.
Garone LM Ammannati E Brush TS Fischer DJ Tos EG Luo J Altobello KL Ciampolillo C Ihley TM Kurosawa E Tiebout A McKenna S 《Endocrinology》2006,147(9):4205-4212
A chimeric recombinant human gonadotropin, termed C3, demonstrates both follitropic and lutropic bioactivities. The alpha-subunit construct for C3 is comprised of the recombinant wild-type human glycoprotein hormone alpha-subunit. The beta-subunit DNA construct for C3 encodes residues 1-145 from human chorionic gonadotropin (hCG)-beta with the exceptions that FSH beta amino acid 88 (D) is substituted for hCG beta amino acid 94 (R) and FSH beta amino acids 95-108 (TVRGLGPSYCSFGE) are substituted for hCG beta amino acids 101-114 (GGPKDHPLTCDDPR). C3 is a potent FSH and LH agonist able to bind and to signal through FSH and LH receptors in vitro. In in vivo bioassays optimized to quantify each type of activity, C3 was found to have lutropin and follitropin potencies at levels similar to those of recombinant human LH and recombinant human FSH, respectively. In immature rats, C3 was sufficient to support the maturation of normal ovarian follicles. Moreover, a significant portion of follicles matured by C3 ruptured in response to an ovulatory hCG stimulus and gave rise to morphologically normal oocytes. Furthermore, a low dose of C3 promoted weight gain in the rodent uterus, suggesting it also supported preparation for implantation without histological evidence of excessive luteinization of the ovary. In summary, the biological properties of C3 indicate that its chimeric nature has resulted in a fully functional, dual-acting human gonadotropin. 相似文献
83.
Tortorano AM Dho G Prigitano A Breda G Grancini A Emmi V Cavanna C Marino G Morero S Ossi C Delvecchio G Passera M Cusumano V David A Bonaccorso G Corona A Favaro M Vismara C Garau MG Falchi S Tejada MR;ECMM-FIMUA Study Group 《Mycoses》2012,55(1):73-79
Critically ill patients admitted to intensive care units (ICU) are highly susceptible to healthcare-associated infections caused by fungi. A prospective sequential survey of invasive fungal infections was conducted from May 2006 to April 2008 in 38 ICUs of 27 Italian hospitals. A total of 384 fungal infections (318 invasive Candida infections, three cryptococcosis and 63 mould infections) were notified. The median rate of candidaemia was 10.08 per 1000 admissions. In 15% of cases, the infection was already present at the time of admission to ICU. Seventy-seven percent of Candida infections were diagnosed in surgical patients. Candida albicans was isolated in 60% of cases, Candida glabrata and Candida parapsilosis in 13%, each. Candida glabrata had the highest crude mortality rate (60%). Aspergillus infection was diagnosed in 32 medical and 25 surgical patients. The median rate was 6.31 per 1000 admissions. Corticosteroid treatment was the major host factor. Aspergillosis was demonstrated to be more severe than candidiasis as the crude mortality rate was significantly higher (63% vs. 46%), given an equal index of severity, Simplified Acute Physiology Score (SAPS-II). The present large nationwide survey points out the considerable morbidity and mortality of invasive fungal infections in surgical as well as medical patients in ICU. 相似文献
84.
85.
Giacomo Emmi Maria Letizia Urban Massimo Imazio Marco Gattorno Silvia Maestroni Giuseppe Lopalco Luca Cantarini Domenico Prisco Antonio Brucato 《Current cardiology reports》2018,20(8):61
Purpose of Review
This review aims to summarize the role of the interleukin-1 (IL-1) blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale and the most relevant clinical studies.Recent Findings
IL-1 is a pivotal cytokine of the innate immune system. Anti-IL-1 agents are currently used for the treatment of several autoimmune and autoinflammatory conditions. Recently, the role of IL-1 has also emerged in cardiovascular diseases. Indeed, two recent randomized controlled trials have shown that the IL-1 receptor antagonist anakinra is effective for the treatment of idiopathic recurrent pericarditis and the IL-1β blocking agent canakinumab is effective in reducing myocardial infarction in people at risk. Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure.Summary
Blocking the IL-1 pathway is a possible new therapeutic strategy, potentially leading to innovative therapies in many acute and chronic cardiovascular diseases.86.
Giulio Cavalli Serena Colafrancesco Giacomo Emmi Massimo Imazio Giuseppe Lopalco Maria Cristina Maggio Jurgen Sota Charles A. Dinarello 《Autoimmunity reviews》2021,20(3):102763
The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-inflammatory cytokine. The IL-1α precursor is constitutively present in nearly all cell types in health, but is released upon necrotic cell death as a bioactive mediator. IL-1α is also expressed by infiltrating myeloid cells within injured tissues. The cytokine binds the IL-1 receptor 1 (IL-1R1), as does IL-1β, and induces the same pro-inflammatory effects. Being a bioactive precursor released upon tissue damage and necrotic cell death, IL-1α is central to the pathogenesis of numerous conditions characterized by organ or tissue inflammation. These include conditions affecting the lung and respiratory tract, dermatoses and inflammatory skin disorders, systemic sclerosis, myocarditis, pericarditis, myocardial infarction, coronary artery disease, inflammatory thrombosis, as well as complex multifactorial conditions such as COVID-19, vasculitis and Kawasaki disease, Behcet’s syndrome, Sjogren Syndrome, and cancer.This review illustrates the clinical relevance of IL-1α to the pathogenesis of inflammatory diseases, as well as the rationale for the targeted inhibition of this cytokine for treatment of these conditions. Three biologics are available to reduce the activities of IL-1α; the monoclonal antibody bermekimab, the IL-1 soluble receptor rilonacept, and the IL-1 receptor antagonist anakinra. These advances in mechanistic understanding and therapeutic management make it incumbent on physicians to be aware of IL-1α and of the opportunity for therapeutic inhibition of this cytokine in a broad spectrum of diseases. 相似文献
87.
88.
89.
Antonio Vitale Giacomo Emmi Giuseppe Lopalco Claudia Fabiani Stefano Gentileschi Elena Silvestri Di Scala Gerardo Florenzo Iannone Bruno Frediani Mauro Galeazzi Giovanni Lapadula Donato Rigante Luca Cantarini 《Clinical rheumatology》2017,36(9):2063-2069
Our aim was to retrospectively assess the role of golimumab as a treatment choice in patients with Behçet’s disease (BD). Seventeen patients diagnosed with BD according to the international criteria were consecutively enrolled; the BD Current Activity Form (BDCAF) was used to evaluate disease activity. After having collected clinical data from patients, statistical analysis was performed to identify differences between the start of therapy and last visit; significance was defined as p < 0.05. The mean duration of golimumab treatment was 18.47 ± 20.8 months. At the time of data enrollment, 12/17 (70.6%) patients were still on golimumab therapy. The mean time required to obtained clinical response was 4.9 ± 5.7 weeks. At 3 months evaluation, golimumab was able to control BD-related manifestations in 16/17 (94.1%) cases; the BDCAF values were significantly decreased at the last follow-up compared to those assessed at the start of golimumab (p = 0.002). The BDCAF improvement was significantly higher among patients co-administered with DMARDs than those undergoing golimumab as monotherapy (p = 0.048). At the last follow-up visit, corticosteroids had been discontinued in 10 (58.8%) patients, while the corticosteroid dosage was significantly lower at the last follow-up visit compared to the start of therapy in those patients already on corticosteroids at the end of the study (p = 0.001). Golimumab is a promising and safe treatment opportunity in BD patients with different systemic involvement, inducing a prompt resolution of clinical manifestations, a meaningful improvement of BDCAF score, and a significant corticosteroid-sparing effect. However, golimumab co-administered with DMARDs has provided better results than in patients undergoing monotherapy. 相似文献
90.
Antonio Brucato Massimo Imazio Paul C. Cremer Yehuda Adler Bernhard Maisch George Lazaros Marco Gattorno Alida L. P. Caforio Renzo Marcolongo Giacomo Emmi Alberto Martini Allan L. Klein 《Internal and emergency medicine》2018,13(6):839-844
In developed countries, more than 80% of cases of acute pericarditis remain without an established diagnosis after a conventional and standard diagnostic approach. These cases are generally labelled as ‘idiopathic’, i.e. without a known cause. This lack of information is a matter of concern for both patients and clinicians. Some years ago, this term reflected the state of the art of scientific knowledge on the topic. Advances have changed this point of view, in light of available molecular techniques like polymerase chain reaction able to identify viral cardiotropic agents in pericardial fluid and biopsies. Furthermore, the remarkable efficacy of interleukin-1 antagonists, a therapy targeting the innate immune response, suggests clinical and pathogenic similarity between a proportion of patients with idiopathic recurrent pericarditis and classical autoinflammatory diseases. So, it seems useful to discuss the pros and cons of using the term “idiopathic” in light of the new knowledge. 相似文献